Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
Patent 6096740 Issued on August 1, 2000. Estimated Expiration Date: 
September 28, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 28, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesHexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents Novel tetrahydrocannabinol type compounds Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents (3S-4S)-7-hydroxy-Ɗ6 -tetrahydrocannabinols Patent #: 4876276 InventorsAssigneeApplicationNo. 011814 filed on 09/28/1998US Classes:514/236.8, Ring chalcogen in the additional hetero ring (e.g., oxazole, etc.)514/100, Polycyclo ring system having the hetero ring as one of the cyclos514/254.11, Polycyclo ring system having the additional oxygen hetero ring as one of the cyclos514/314, Additional hetero ring attached directly or indirectly to the quinoline ring system by nonionic bonding514/325, Polycyclo ring system is tricyclo-carbocyclic514/382, Additional chalcogen containing hetero ring514/455, Chalcogen bonded directly to ring carbon of the hetero ring544/109, Hetero ring in ionically bonded moiety544/375, Polycyclo ring system having the additional hetero ring as one of the cyclos546/135, Additional hetero ring containing546/282.7, Polycyclo ring system having the additional hetero ring as one of the cyclos548/252, Chalcogen attached indirectly to the tetrazole ring by nonionic bonding549/291Acyclic -C(=X)-, wherein X is chalcogen, bonded directly to the lactone ringExaminersPrimary: McKane, Joseph K.Assistant: Solola, Taofiq Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/352A61K 031/496 C07D 295/037 C07D 311/80 C07D 453/04 AbstractThe present invention relates to pharmaceutical compositions for preventing or alleviating neurotoxicity. Said pharmaceutical compositions comprise as their active ingredient the stereospecific (+) enantiomers, having (3S,4S) configuration, of Ɗ6 -tetrahydrocannabinol (THC) type compounds of general formula (I), as defined hereinbelow. ##STR1##Other References
Field of SearchRing chalcogen in the additional hetero ring (e.g., oxazole, etc.)Additional hetero ring attached directly or indirectly to the quinoline ring system by nonionic bonding Polycyclo ring system is tricyclo-carbocyclic Additional chalcogen containing hetero ring Chalcogen bonded directly to ring carbon of the hetero ring Hetero ring in ionically bonded moiety Polycyclo ring system having the additional hetero ring as one of the cyclos Additional hetero ring containing Polycyclo ring system having the additional hetero ring as one of the cyclos Chalcogen attached indirectly to the tetrazole ring by nonionic bonding Plural chalcogens bonded directly to the tricyclo ring system |
| ||||||||||||||
